A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
- Indications Bladder cancer; Renal cell carcinoma
- Focus Adverse reactions
- 21 Mar 2018 Planned End Date changed from 31 May 2019 to 31 May 2020.
- 21 Mar 2018 Planned primary completion date changed from 31 May 2018 to 31 May 2019.
- 28 Sep 2017 Planned primary completion date changed from 1 May 2018 to 31 May 2018.